CancerDrs Find care

Testicular Cancer clinical trials in Ohio

9 actively recruiting testicular cancer trials at 45 sites across Ohio.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Network

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it dev…

Sponsor: Children's Oncology Group
NCT ID: NCT03067181
Sites in Ohio:
  • Children's Hospital Medical Center of Akron — Akron, Ohio
  • OhioHealth O'Bleness Hospital — Athens, Ohio
  • Strecker Cancer Center-Belpre — Belpre, Ohio
  • Adena Regional Medical Center — Chillicothe, Ohio
  • Good Samaritan Hospital - Cincinnati — Cincinnati, Ohio
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…

Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in Ohio:
  • Children's Hospital Medical Center of Akron — Akron, Ohio
  • Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
  • Rainbow Babies and Childrens Hospital — Cleveland, Ohio
  • Cleveland Clinic Foundation — Cleveland, Ohio
  • Nationwide Children's Hospital — Columbus, Ohio
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Ohio:
  • Indu and Raj Soin Medical Center — Beavercreek, Ohio
  • Strecker Cancer Center-Belpre — Belpre, Ohio
  • Saint Elizabeth Boardman Hospital — Boardman, Ohio
  • Dayton Physicians LLC-Miami Valley South — Centerville, Ohio
  • Miami Valley Hospital South — Centerville, Ohio
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody, in participants with platinum-refractory/resistant ov…

Sponsor: Context Therapeutics Inc.
NCT ID: NCT06515613
Sites in Ohio:
  • Gabrail Cancer Center — Canton, Ohio
View on ClinicalTrials.gov →
NA Recruiting Network

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.

Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT05108298
Sites in Ohio:
  • Strecker Cancer Center-Belpre — Belpre, Ohio
  • Adena Regional Medical Center — Chillicothe, Ohio
  • Good Samaritan Hospital - Cincinnati — Cincinnati, Ohio
  • Bethesda North Hospital — Cincinnati, Ohio
  • TriHealth Cancer Institute-Westside — Cincinnati, Ohio
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Ohio:
  • Massive Bio SYNERGY-AI site — Cincinnati, Ohio
  • Massive Bio SYNERGY-AI site — Columbus, Ohio
  • Massive Bio SYNERGY-AI site — Mayfield Heights, Ohio
View on ClinicalTrials.gov →
Recruiting Academic/Other

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…

Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Ohio:
  • Aultman Alliance Community Hospital — Alliance, Ohio
  • Aultman Hospital — Canton, Ohio
View on ClinicalTrials.gov →
Recruiting Industry

DESTINY-PANTUMOUR04

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have n…

Sponsor: AstraZeneca
NCT ID: NCT07124000
Sites in Ohio:
  • Research Site — Canton, Ohio
  • Research Site — Maumee, Ohio
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20